Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
This activity is supported by an educational grant from Lilly.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com or call (609) 325-4668
Oncology Best Practice™:
Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease Progression
September 2017 - January 2018
The management of patients with advanced non–small cell lung cancer (NSCLC) who have progressed following first-line therapy has increased in complexity due to the expanding subtypes of NSCLC and corresponding therapeutic options recently made available. As new biomarkers and patient characteristics continue to emerge that assist clinicians in predicting responsiveness to particular approaches, practitioners will need updates that allow them to optimize outcomes in lung cancer management. Education is therefore needed to address the evidence that informs therapeutic selection after disease progression, circumstances that should guide switching of therapies, and methods to proactively manage treatment-related adverse events.
To meet this educational need, Oncology Best Practice™ will bring nationally renowned experts in NSCLC directly to leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. These 1-hour interactive meetings will address the therapeutic needs that persist for patients with lung cancer, as well as current and emerging therapies to address these medical needs. Ample discussion time will allow participants to interact with expert faculty to address challenges in their practice.
What will attending an Oncology Best Practice™ allow me to do?
This educational activity is directed toward medical oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are invited to participate.
At the conclusion of this activity, participants will be better prepared to:
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018